IDXX stock forecast, quote, news & analysis
Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock... Show more
IDEXX Laboratories (IDXX) Stock Analysis: Innovation Momentum Meets a Critical Earnings Week
Key Takeaways
- IDEXX Laboratories shares climbed approximately 4% over the last 30 days, closing at $559.07 on July 31, 2026, reflecting cautious optimism ahead of the company's second-quarter earnings report.
- The company delivered strong Q1 2026 results in May, with revenue of $1.14 billion and EPS of $3.47, both exceeding Wall Street estimates and prompting management to raise full-year guidance.
- IDEXX's innovation engine remains a central theme — the inVue Dx platform, Cancer Dx expansion, and growing AI integration in diagnostics are key long-term growth drivers.
- Analyst sentiment is broadly constructive, with a consensus Moderate Buy rating and an average 12-month price target of roughly $707, implying over 26% upside from recent levels.
- Investors face two near-term catalysts: Q2 2026 earnings on August 4 and the company's 2026 Investor Day on August 13, likely to set the tone for the remainder of the year.
Current Market Snapshot
IDEXX Laboratories stock has traded in a relatively contained range over the past 30 days, moving from a close of $537.58 on July 1 to $559.07 on July 31 — a gain of roughly 4%. The shares have oscillated between an intra-month low near $534 and a high just above $576, reflecting a market that is weighing strong underlying business fundamentals against persistent macro uncertainty. With a market capitalization of approximately $44 billion and a 52-week range of $518.55 to $769.98, the stock sits well below its prior-year highs, yet the short-term trend has been modestly constructive. Broader sentiment in the medical technology and animal health sector remains supportive, though volatility in veterinary clinic visit volumes and consumer discretionary spending on pet care continue to draw investor attention.
IDEXX Laboratories (IDXX) Business Overview and Competitive Position
IDEXX Laboratories is a global leader in pet healthcare innovation, developing and distributing diagnostic products, instruments, software, and reference laboratory services primarily for the companion animal veterinary market. Headquartered in Westbrook, Maine, and employing approximately 11,000 people, the company serves customers in more than 175 countries. Its Companion Animal Group (CAG) accounts for the overwhelming majority of revenue, driven by recurring diagnostics revenue from IDEXX VetLab consumables, reference laboratory services, and rapid assay tests. The company also operates smaller but steady Water and Livestock, Poultry and Dairy (LPD) segments. IDEXX's competitive moat rests on a large installed base of premium benchtop analyzers — including Catalyst, SediVue, and the newer inVue Dx platform — which generate an annuity-like stream of consumable revenue. The company's razor-and-blade business model, combined with continuous diagnostic menu expansion and software integration, positions it as the dominant player in veterinary diagnostics. Institutional ownership stands at roughly 88%, underscoring the stock's profile as a high-quality healthcare compounder.
Recent Developments Driving IDXX
Several developments have shaped investor sentiment around IDEXX in recent weeks. On the corporate governance front, CEO Jay Mazelsky announced a leadership transition, with President Mike Erickson set to take the helm — a move the market has absorbed without disruption. The company used a Stifel investor conference appearance to highlight its innovation pipeline, emphasizing AI-driven diagnostic capabilities, the controlled rollout of inVue Dx FNA (fine-needle aspiration), and growing international adoption of the Cancer Dx platform. These product-cycle narratives reinforce IDEXX's long-term growth trajectory.
On Wall Street, analyst actions have been mixed but generally constructive. William Blair reiterated a Buy rating, while Bank of America and Stifel maintained positive stances with price targets of $660 and $675, respectively. UBS and Citigroup adopted more cautious Neutral ratings, both pointing to valuation and slower visit-volume recovery as headwinds. Weiss Ratings and Wall Street Zen each lowered their ratings modestly. Meanwhile, institutional activity showed two-sided positioning — Bessemer Group increased its stake while KBC Group reduced its position by 44% — though aggregate institutional ownership remains high at nearly 88%.
The most consequential near-term event is the upcoming Q2 2026 earnings report on August 4. Consensus estimates call for EPS of $3.95 on revenue of approximately $1.20 billion, representing year-over-year growth of roughly 9% and 8%, respectively. IDEXX has beaten estimates in each of the last four quarters.
Trending AI Robots
For investors seeking data-driven approaches to navigate stocks like IDEXX Laboratories, Tickeron's Trending AI Robots page offers a curated view of top-performing AI trading bots. Tickeron hosts hundreds of AI-powered trading bots that collectively trade thousands of tickers across multiple strategies, timeframes, and performance metrics. Only the most consistently effective and relevant bots are surfaced in the Trending section, giving traders a streamlined way to discover algorithmic strategies aligned with current market conditions. Bots vary by approach — some specialize in momentum, others in swing trading or longer-term trend following — allowing users to find strategies that match their individual trading style. Exploring the Trending AI Robots page can help investors identify actionable signals in real time.
2026 Outlook and What Investors Should Watch
IDEXX enters the second half of 2026 with raised full-year guidance calling for revenue of $4.675 billion to $4.760 billion and EPS of $14.45 to $14.90, implying reported earnings growth of 11% to 14% at the midpoint. Key drivers to monitor include the trajectory of U.S. veterinary clinic visit volumes, which declined modestly in Q1 but showed signs of stabilization. The pace of inVue Dx placements — targeted at 5,500 for the full year — and the international expansion of Cancer Dx will serve as barometers of innovation-driven growth. Macroeconomic factors such as consumer spending on pet healthcare, foreign exchange volatility, and potential tariff implications on globally sourced components also warrant attention. The August 13 Investor Day is expected to provide deeper insight into IDEXX's multi-year product roadmap, AI strategy, and long-term financial targets, making it a pivotal event for the investment narrative in the months ahead.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
IDXX in downward trend: price may decline as a result of having broken its higher Bollinger Band on August 04, 2026
IDXX broke above its upper Bollinger Band on August 04, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options. The A.I.dvisor looked at 39 similar instances where the stock broke above the upper band. In of the 39 cases the stock fell afterwards. This puts the odds of success at .
Technical Analysis (Indicators)
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on August 14, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on IDXX as a result. In of 92 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .
The Moving Average Convergence Divergence Histogram (MACD) for IDXX turned negative on August 14, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 43 similar instances when the indicator turned negative. In of the 43 cases the stock turned lower in the days that followed. This puts the odds of success at .
IDXX moved below its 50-day moving average on August 14, 2026 date and that indicates a change from an upward trend to a downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where IDXX declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
Bullish Trend Analysis
The Stochastic Oscillator demonstrated that the ticker has stayed in the oversold zone for 2 days, which means it's wise to expect a price bounce in the near future.
The 10-day moving average for IDXX crossed bullishly above the 50-day moving average on August 04, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In of 20 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are .
Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where IDXX advanced for three days, in of 290 cases, the price rose further within the following month. The odds of a continued upward trend are .
The Aroon Indicator entered an Uptrend today. In of 172 cases where IDXX Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .
Fundamental Analysis (Ratings)
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating very strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating fairly steady price growth. IDXX’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (27.027) is normal, around the industry mean (57.573). P/E Ratio (38.884) is within average values for comparable stocks, (149.507). IDXX's Projected Growth (PEG Ratio) (3.389) is slightly higher than the industry average of (1.651). IDXX has a moderately low Dividend Yield (0.000) as compared to the industry average of (0.007). P/S Ratio (9.737) is also within normal values, averaging (9.744).
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. IDXX’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 91, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a manufacturer of animal health products
Industry MedicalSpecialties